The independent financial analyst theScreener just requalified the general evaluation of INTREXON CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date September 3, 2019, the closing price was US...
Summary Marketline's Aevi Genomic Medicine, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Aevi Genomic Medicine, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdo...
Summary Intrexon Corp (Intrexon), formerly Genomatix Corp is a provider of therapeutic solutions. The company operates through its divisions such as human therapeutics, protein production, industrial products, agricultural biotech, and animal sciences. Its human therapeutics division develops therapeutic product candidates for lysosomal storage diseases, hematological disorders, metabolic diseases, infectious diseases, and autoimmune disorders. Intrexon’s UltraVector platform produces and opt...
BOCA RATON, Fla.--(BUSINESS WIRE)-- Ominto, Inc. (Nasdaq:OMNT), a growth company with global operations in the e-commerce, marketing, and entertainment industries, today announced that it has notified the Nasdaq Stock Market of its intent to withdraw its common stock, par value 0.001 per share, from listing on the Nasdaq Capital Market. The Company intends to file with the Securities and Exchange Commission, and Nasdaq, a Form 25 relating to the delisting of its common stock on May 24, 2018. It is anticipated that the delisting will b...
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2018. “The first quarter of 2018 was all about executing on our three key business priorities of optimizing the value of TRULANCE, ensuring a strong financial foundation, and continuing to explore all strategic business development opportunities,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.